Philip E. Thorpe, Ph.D.

Philip E. Thorpe, Ph.D., professor of pharmacology at UT Southwestern Medical Center in Dallas, died on March 30, 2013, at the age of 62. Thorpe had been an AACR member since 1992 and was involved in the Cancer Immunology Working Group and the Tumor Microenvironment Working Group.

Thorpe, who held the Serena S. Simmons distinguished chair in cancer immunopharmacology at UT Southwestern, was known for his research into the development of novel drugs that target tumor blood vessels. He had been serving as a scientific advisor to Peregrine Pharmaceuticals Inc., developing novel therapeutics.

Born on July 10, 1951, Thorpe graduated from the University of Liverpool, in Liverpool, England, in 1972 and then received his doctorate in immunology from London’s Clinical Research Centre in 1976. Before joining UT Southwestern in 1991, Thorpe was the director of the drug targeting laboratory at the Imperial Cancer Research Fund in London.

Thorpe received the American Cancer Society Award of Excellence in 1999 and the Texas State Legislature Award for Research Excellence in 1997. Additionally, he was one of the first recipients of the Pierce Immunotoxin Award for his outstanding contributions to immunotoxin research.